INTRODUCTION

Drug metabolism involves CYP450 and drug transporters in the liver. The CYP450 superfamily, which consists of at least 11 enzyme families, is involved in >80% of phase I-dependent drug metabolism (Ofotokun, 2005). CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are especially important for drug metabolism in humans (Wienkers and Heath, 2005).

Drug transporters located in the membrane regulate drug absorption, distribution, and elimination by pumping molecules across cellular barriers (Guo et al., 2011). OATP transporters are drug influx transporters that regulate the cellular uptake of a number of endogenous compounds and clinically important drugs (Kalliokoski and Niemi, 2009).

Combination therapy is a universal practice in patients with more than one disease or condition. However, the administration of two or more drugs can lead to drug-drug interactions when the metabolism of one drug is altered by another. Such interactions can also occur when CYP450 expression or activity is altered by long-term use of a drug (Lin and Lu, 1998).

Bosentan has mainly been approved for the treatment of pulmonary arterial hypertension, but may also have beneficial effects on other conditions such as essential hypertension, chronic heart failure, and subarachnoid hemorrhage (Dingemans and van Giersbergen, 2004). Bosentan induces and is also metabolized by CYP2C9 and CYP3A4; its inhibition potentially affects drug influx transporters such as OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.

Key Words: Drug-drug interaction, CYP450, OATP transporters, Rifampin, Bosentan

Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes

Kyoung-Moon Han1,*, Sun-Young Ahn1,†, Hyewon Seo1, Jaesuk Yun1, Hye Jin Cha1, Ji-Soon Shin1, Young-Hoon Kim1, Hyungsoo Kim1, Hye-kyung Park1 and Yong-Moon Lee2

1Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 28159, 2College of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea

Abstract

The incidence of polypharmacy—which can result in drug-drug interactions—has increased in recent years. Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators. In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro. HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner. In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 μM bosentan+200 μM rifampin. Rifampin also reduced gene expression of OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.

Key Words: Drug-drug interaction, CYP450, OATP transporters, Rifampin, Bosentan
(Williamson et al., 2013).

The present study investigated the effects of drug-drug interactions on the expression and activity of CYP450 and drug influx transporters (OATP1B1, OATP1B3, and OATP2B1) in cryopreserved human hepatocytes. To evaluate this, bosentan and rifampin were used as a substrate and an inhibitor, respectively, of OATP transporters. The results suggest that bosentan influx by inhibition of OATP transporters alters CYP2C9 and CYP3A4 expression and activities.

**MATERIALS AND METHODS**

**Reagents and chemicals**

- Rifampin, diphenhydramide hydrochloride (98%), dimethyl sulfoxide (DMSO), ammonium acetate, acetonitrile Chromasolv (ACN), formic acid, dexamethasone, dexamethasone, thi-azolyl blue tetrazolium bromide (MTT), and methanol Chromasolv were purchased from Sigma-Aldrich (St. Louis, MO, USA). Bosentan was purchased from Actelion Pharmaceuticals (Allschwil, Switzerland). Cryopreserved human hepatocytes, HEK293 cells overexpressing OATP1B1, OATP1B3, and OATP2B1 transporter, HEK293 mock cells, phosphate-buffered saline (PBS), Gentest High Viability CryoHepatocyte Recovery kit, hepcytate culture medium, ITS+ culture supplement, Dulbecco’s Modification Eagle’s Medium (DMEM), Minimal Essential Medium (MEM) non-essential amino acid solution, epidermal growth factor (EGF), and Hank’s balanced salt solution (HBSS) were purchased from Corning (Corning, NY, USA). Penicillin/streptomycin, William’s E medium (without phenol red), fetal bovine serum (FBS), L-glutamine, gentamycin sulfate, SYBR Green ER qPCR Supermix, and Superscript First-strand Synthesis kit were purchased from Life Technologies (Burlington, ON, Canada). Sodium butyrate solution and testosterone were purchased from EMD-Millipore (Darmstadt, Germany) and Acros (Geel, Belgium), respectively. Easy Spin Total RNA extraction kit was purchased from iNtRON (Seongnam, Korea).

**Culture of cryopreserved human hepatocytes and OATP transporters-overexpressing cells**

Three different cryopreserved human hepatocytes cell lines (Table 1) were thawed using the BD Gentest High Viability CryoHepatocyte Recovery kit. Cells were seeded in 24-well collagen I-coated plates (4×10^5 cells/well) and incubated at 37°C in a humidified atmosphere of 5% CO₂. After 6 h, the medium was replaced with 500 µl of William’s E medium supplemented with 10% FBS, 5 mM MEM non-essential amino acids, and 100 U/ml penicillin-streptomycin and seeded in 24-well poly-D-lysine plates (4×10^5 cells/well), followed by incubation at 37°C in a low-humidity atmosphere of 5% CO₂. After 4 h, the medium of OATP1B1- and OATP1B3-overexpressing cell cultures was replaced with DMEM with 2 mM sodium butyrate, and the medium of OATP2B1-overexpressing cell cultures was replaced with DMEM (Jeong et al., 2015).

**Drug treatment**

Hepatocytes were treated with bosentan (2, 10, 20, 100 µM) and rifampin (0, 2, 20, and 200 µM) for 48 h, with a medium change every 24 h. This was followed by treatment with rifampin only (2, 20, 50, 100, and 200 µM) for 48 h, with a medium change every 24 h. Control cells were treated with 0.1% (v/v) DMSO. Cells were incubated at 37°C in a humidified atmosphere of 5% CO₂.

**Inhibition of OATP transporter uptake**

Uptake by OATP transporters was examined in OATP transporter-overexpressing HEK293 cells and hepatocytes. Cells overexpressing OATP1B1, OATP1B3, and OATP2B1 transporters were washed twice with HBSS and incubated in HBSS for 10 min at 37°C, followed by treatment with bosentan (20 µM) and rifampin (0, 0.01, 0.1, 1, 5, 10, 50, 100, and 500 µM for HEK293 cells and 0, 2, 20, 50, 100, and 200 µM for hepatocytes) in HBSS for 10 min at 37°C. Cells were washed three times with ice-cold HBSS, and 80% ACN was added for 20 min at room temperature to lyse the cells. The lysate was collected in 1.5-ml tubes and centrifuged at 14,000 rpm for 3 min at 4°C. A 5-µl volume of supernatant was injected into a 1260 Infinity high-performance liquid chromatography (HPLC) system (Agilent Technologies, Santa Clara, CA, USA) equipped with a UK-C18 column (2.1×50 mm, 3.0 µm). To confirm the effects of rifampin (inhibitor) on bosentan (substrate), the latter drug was quantified with a 6460 triple quadrupole mass spectrometer (Agilent Technologies). Elution was carried out using a mixture of mobile phases A (0.1% formic acid in distilled water) and B (0.1% formic acid in ACN). Analytes were separated for 10 min under the following gradient conditions: 95% mobile phase B (0-2 min); 5% mobile phase B for 2-2.1 min; 95% mobile phase B for 2.1-5 min; and 95% mobile phase B for 5-10 min. Bosentan was observed for the transition of precursor to product ion at m/z 252.2→202.2 m/z by multiple reaction monitoring (MRM). For hepatic concentrations (IC₅₀) of OATP transporters were calculated using GraphPad Prism v.5.01 software (GraphPad Inc., La Jolla, CA, USA).

**Determination of human hepatocyte viability after bosentan and rifampin treatment**

Cell viability was evaluated with the MTT assay (Han et al., 2015). MTT (5 mg/ml) added to the cells for 4 h then removed. Cells were lysed in DMSO. Absorbance was measured at 570 nm using a SpectraMAX M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA).

**Total RNA extraction and purification**

Total RNA was extracted using an RNA extraction kit according to the manufacturer’s instructions. Briefly, hepato-

---

**Table 1. Information on cryopreserved human hepatocyte donors**

|                | HMC505 | HMC1026 | HMC1051 |
|----------------|--------|---------|---------|
| Gender         | Male   | Male    | Male    |
| Age (year)     | 65     | 49      | 51      |
| Race           | Caucasian | Caucasian | Caucasian |

---

Han et al. Polypharmacy and Interaction of OATP Transporters and CYP450

---

289 www.biomolther.org
Table 2. Sequences of CYP2C9, 3A4 and OATP transporters primers used for qRT-PCR

| Gene     | Sequence (5'-3') | Product size (bp) |
|----------|-----------------|------------------|
| CYP2C9   | F-cccttggaagttccccgagc | 200              |
|          | R-cccggtgcttctccggcagc |                 |
| CYP3A4   | F-cccttggaagttccccgagc | 353              |
|          | R-cccggtgcttctccggcagc |                 |
| OATP1B1  | F-actgtctttgcatgtgctgg | 346              |
|          | R-ggcattccaaaggtttctca |                 |
| OATP1B3  | F-gtccagtctgattggctttgca | 111             |
|          | R-caccccaacaggtttctcaag |                 |
| OATP2B1  | F-gtccagtctgattggctttgca | 265             |
|          | R-gccgttgccaaataagctcctcc |         |
| GAPDH    | F-ccacttggcttcacccccttc | 272              |
|          | R-gtccccctgacacggctgg |                 |

CDNA synthesis by reverse transcription

CDNA was synthesized using the SuperScript First-strand Synthesis kit according to the manufacturer’s instructions. Briefly, a mixture consisting of 1 μg RNA, 1 μl of 50 μM oligo(d)T, 1 μl of 10 mM dNTP, and diethylpyrocarbonate (DEPC)-treated water was incubated at 65°C for 5 min, and 10 μl of the mixture were combined with 10 μl of cDNA synthesis mixture and reacted at 50°C for 50 min followed by 85°C for 5 min.

Quantitative real-time (qRT)-PCR analysis of CYP450 and OATP transporter expression

CDNA (1 μg) was amplified on an iQ5 qRT-PCR detection system (Bio-Rad, Hercules, CA, USA). The reaction mixture consisted of 2X SYBR Green ER qPCR Supermix (10 μl) and 20 pmol forward and reverse primers (1 μl each) (Table 2). CYP2C9 and CYP3A4 primers were designed using FastPCR software (PrimerDigital, Helsinki, Finland). OATP transporter-specific primers have been previously described (Sekitani et al., 2009; Fujiwara et al., 2014). The reaction conditions were as follows: 50°C for 2 min; 95°C for 10 min; 40 cycles of 95°C for 30 s, 60°C for 45 s, and 72°C for 30 s; and a melting curve from 55°C-81°C at 1°C/30 s. Gene expression levels were quantified relative to the internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH). PCR amplification products were qualitatively evaluated by melting curve analysis (Perez et al., 2003).

Determination of CYP450 enzymatic activity

CYP2C9 and CYP3A4 enzymatic activity was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Hepatocyte culture medium containing bosentan and rifampin was removed from plates, which were rinsed with PBS. Hepatocyte culture medium containing CYP450 substrates (100 μM diclofenac for CYP2C9 and 200 μM testosterone for CYP3A4) was added to the hepatocyte monolayers to measure enzymatic activity at 37°C in a humidified atmosphere of 5% CO2 for 60 min. At the end of the incubation period, 100 μl of reaction medium were added to 25 μl of stop solution consisting of 10 mM ammonium acetate in methanol and 5 μl of the internal standard consisting of 50 ng/ml diphenhydramine.

A 5-μl volume of reaction mixture was injected into a 1260 Infinity HPLC system equipped with a poroshell SB C18 column (2.1×100 mm, 2.7 μm). Quantification of 4-hydroxydiclofenac and 6β-hydroxytestosterone was carried out on a 6460 triple quadrupole mass spectrometer. Elution was carried out with a mixture of mobile phase A (10 mM ammonium acetate in distilled water) and mobile phase B (10 mM ammonium acetate in methanol). Analytes were separated for 10 min under the following gradient conditions: 95% mobile phase A:5% mobile phase B at 0-2 min; 5% mobile phase A:95% mobile phase B at 5-7 min; and 95% mobile phase A:5% mobile phase B at 7.10-10 min. 4-Hydroxydiclofenac, 6β-hydroxytestosterone, and the internal standard (diphenhydramine) were observed by MRM for the transition of precursor to product ions at m/z 312.0→230.0, 305.3→269.2, and 256.2→167.1, respectively. Enzymatic activity was calculated using the following formula.

\[
\text{Enzyme activity} = \frac{\text{Calculated concentration (μM) × Incubation volume (μl)}}{0.3 \times \text{Confluency (10}^6 \text{cells per well) × Incubation time (min)}}
\]

Statistical analysis

Data are expressed as mean ± SEM and were evaluated by one-way ANOVA analysis of variance with Bonferroni’s post hoc test using Sigma Plot v.13.0 software (Systat Software Inc., San Jose, CA, USA). Statistical significance was set as \( p<0.05 \). Values were compared to those of the control or to samples treated with 20 μM bosentan.

RESULTS

Inhibition of OATP transporter uptake of bosentan by rifampin

To evaluate the effects of inhibiting uptake by OATP transporters, we measured uptake in HEK293 cells overexpressing OATP1B1, OATP1B3, and OATP2B1 transporter that were treated with bosentan and rifampin for 10 min. Uptake by all three transporters decreased as a function of rifampin concentration (Fig. 1). Values ranged from 0.370-0.104 pmol/10^6 cells per well/min for OATP1B1; 0.130-0.034 pmol/10^6 cells per well/min OATP1B3; and 0.410-0.142 pmol/10^6 cells per well/min for OATP2B1. There was no uptake by HEK293 mock-treated cells. The IC50 values of bosentan for OATP1B1, OATP1B3, and OATP2B1 transporter were 3.79, 3.41, and 20.74 μM, respectively.

Cytotoxicity of bosentan and rifampin

To evaluate cytotoxicity of bosentan and rifampin, human hepatocytes from three donors were treated with bosentan and rifampin for 48 h. These drugs had no effect on cell viability when administered individually (Fig. 2A, 2B) or in combination (Fig. 2C).
Effect of bosentan and rifampin on CYP2C9 and CYP3A4 levels

To assess the effects of combined bosentan and rifampin treatment, human hepatocytes from three donors were co-treated with bosentan (20 μM) and rifampin (0, 0.01, 0.1, 1, 5, 10, 50, 100, and 500 μM). Data are expressed as the mean bosentan uptake activity ± SEM of three replicates.

OSATP1B1 (bosentan)
OSATP1B3 (bosentan)
OSATP2B1 (bosentan)

Fig. 1. Inhibition of uptake by OATP transporters in OATP-overexpressing HEK293 cells. Uptake by (A) OATP1B1, (B) OATP1B3, and (C) OATP2B1 was measured in HEK293 cells treated with bosentan (20 μM) and rifampin (0, 0.01, 0.1, 1, 5, 10, 50, 100, and 500 μM). Data are expressed as the mean bosentan uptake activity ± SEM of three replicates.

Fig. 2. Cytotoxicity of bosentan and rifampin in human hepatocytes. Cytotoxicity of bosentan (A), rifampin (B) and bosentan+rifampin (C) was evaluated in hepatocytes treated with bosentan (2, 10, 20, and 100 μM), rifampin (0, 2, 10, 20, 100 and 200 μM), or bosentan (20 μM)+rifampin (0, 2, 10, 20, 100 and 200 μM). Data are expressed as the mean cytotoxicity ± SEM of three replicates.
μM bosentan+200 μM rifampin (Fig. 3A). Similar trends were observed for CYP3A4: gene expression was upregulated by 77.00-, 5.75-, and 10.41-fold in HMC505, HMC1026, and HMC1051 cells upon treatment with 20 μM bosentan relative to the values reported for the control group and was increased by 107.73-, 19.96-, and 21.39-fold, respectively, in the presence of 20 μM bosentan+20 μM rifampin as compared to that observed in the presence of 20 μM bosentan. However, expression was downregulated by 25.77-, 2.03-, and 4.08-fold, respectively, upon co-treatment with 20 μM bosentan+200 μM rifampin (Fig. 3B). The enzymatic activity of CYP2C9 was increased by 2.51-, 1.94-, and 2.36-fold in HMC505, HMC1026, and HMC1051 cells by treatment with 20 μM bosentan relative to the control values. Compared to treatment with 20 μM bosentan, co-administration of 20 μM bosentan+20 μM rifampin increased the activity in these cells by 3.51-, 3.39-, and 3.93-fold, respectively. However, co-treatment with 20 μM bosentan+200 μM rifampin decreased the activity by 1.72-, 1.44-, and 2.06-fold, respectively, relative to that reported for the 20 μM bosentan group (Fig. 3C). Similar trends were observed for CYP3A4 activity, which was increased by 5.06-, 3.15-, and 2.06-fold in HMC505, HMC1026, and HMC1051 cells, respectively, by 20 μM bosentan treatment as compared to that observed for the untreated cells. The activity was further increased by 6.97-, 7.01-, and 5.51-fold upon co-administration of 20 μM bosentan+20 μM rifampin relative to that observed for the 20 μM bosentan-only group. However, the activity was decreased by 2.08-, 1.98-, and 1.50-fold, respectively, as compared to that in cells treated with 20 μM bosentan+200 μM rifampin (Fig. 3D).

**Effect of rifampin on CYP2C9 and CYP3A4 levels**

CYP2C9 and CYP3A4 levels were downregulated by treatment with 20 μM bosentan combined with 200 μM rifampin. The effects of rifampin were investigated in HMC505, HMC1026, and HMC1051 hepatocytes treated with rifampin for 48 h. CYP2C9 expression increased in all cell lines upon treatment with 0, 2, 20, and 50 μM rifampin; for example, at 50 μM rifampin, the expression level was 3.86-, 2.89-, and 3.17-fold higher in HMC505, HMC1026, and HMC1051 cells, respectively, than that in controls. However, rifampin concentrations of 100 and 200 μM inhibited CYP2C9 expression; at 200 μM, the levels were 1.31-, 1.62-, and 1.40-fold lower in
Effect of bosentan and rifampin on OATP transporters

We evaluated the effect of bosentan and rifampin on OATP transporters’ gene expression in hepatocytes treated with rifampin for 48 h. OATP1B1, OATP1B3, and OATP2B1 transporter gene expression levels were downregulated relative to that in controls in a rifampin concentration-dependent manner in three donor hepatocytes. At 200 μM rifampin, OATP1B1 gene expression levels were 0.52-, 0.42-, and 0.67-fold lower; OATP1B3 levels were 0.40-, 0.47-, and 0.39-fold lower; and OATP2B1 levels were 0.41-, 0.14-, and 0.50-fold lower in HMC505, HMC1026, and HMC1051 cells, respectively, as compared to the values for the respective control groups (Fig. 5).

We assessed the effects of bosentan and rifampin on drug uptake by OATP transporters in human hepatocytes treated with 20 μM bosentan+200 μM rifampin for 48 h. Bosentan uptake by OATP transporters decreased to 276.62, 68.21, and 86.88 pmol/10^6 cell per well/min in HMC505, HMC1026, and HMC1051 cells, respectively, in a rifampin concentration-dependent manner relative to that in cells treated with 20 μM bosentan alone (Fig. 6).

DISCUSSION

We studied drug-drug interactions between CYP450 and OATP transporters in cryopreserved human hepatocytes treated with bosentan and rifampin. Previous studies have reported that the maximum serum concentration (Cmax) of bosentan is 22.5 μM and that unbound affinity constant (K_u) of bosentan is 2.5 μM (Sasayama et al., 2005). Another study showed that the unbound affinity constant (K_u) of bosentan is 22.5 μM.
in human hepatocytes (Menochet et al., 2012). To conclusively establish inhibitor-substrate interaction effects, we used 20 μM bosentan (10×C_{max}), which yielded sufficient influx through OATP transporters as endogenous substrates.

Co-treatment with bosentan and rifampin resulted in a temporary increase in bosentan influx concentrations; rifampin also inhibited bosentan uptake into cells overexpressing OATP1B1 and OATP1B3 in a concentration-dependent manner, and its IC_{50} values for OATP1B1 and OATP1B3 were 3.2 and 1.6 μM, respectively (van Giersbergen et al., 2007). This is similar to our results, which showed that rifampin IC_{50} values for OATP1B1 and OATP1B3 transporter were 3.79 and 3.41 μM, respectively, in HEK293 cells overexpressing these transporters and treated with bosentan and rifampin.

CYP2C9 and CYP3A4 enzyme activity was increased by treatment with 20 μM bosentan+2 or 20 μM rifampin, but was decreased by 20 μM bosentan+200 μM rifampin in hepatocytes (Fig. 3). However, high concentrations of rifampin and bosentan+rifampin were not toxic to human hepatocytes (Fig. 2), consistent with a previous report (Zhang et al., 2012).

Unexpectedly, the effects of treatment with rifampin alone were similar to those of bosentan and rifampin co-treatment (Fig. 3, 4). CYP2C9 and CYP3A4 were inhibited by a high concentration of rifampin, which acts as both OATP transporters substrate and inhibitor. High rifampin concentrations also inhibited OATP transporters, thereby blocking the influx of both rifampin and bosentan into cells. This was confirmed by analyzing OATP transporters gene expression and bosentan uptake by the OATP transporters in hepatocytes (Fig. 5, 6).

In conclusion, we found that OATP transporter gene expression as well as bosentan uptake decreased as a function of rifampin concentration. Our findings suggest that rifampin and bosentan interact to modulate the expression and activities of CYP450 and OATP transporters, which should be taken into account when prescribing both drugs to patients.

**ACKNOWLEDGMENTS**

This study was supported by the Ministry of Food and Drug Safety of Korea (15181MFDS483).

**REFERENCES**

Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. and Darst, S. A. (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cef* **104**, 901-912.

Dingemanse, J. and van Giersbergen, P. L. (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. *Clin. Pharmacokinet*. **43**, 1089-1115.

Fujiwara, R., Takenaka, S., Hashimoto, M., Narawa, T. and Itoh, T.
(2014) Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Sci. Rep. 4, 5251.

Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J. L., Green, B., Deng, H., Kaput, J. and Ning, B. (2011) Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39, 528-538.

Han, J. Y., Ahn, S. Y., Yoo, J. H., Nam, S. Y., Hong, J. T. and Oh, K. W. (2015) Alleviation of kainic acid-induced brain barrier dysfunction by 4-o-methylnonokiol in in vitro and in vivo models. Biomed Res. Int. 2015, 893163.

Jeong, H. U., Kwon, M., Lee, Y., Yoo, J. S., Shin, D. H., Song, I. S. and Lee, H. S. (2015) Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide. Drug Des. Devel. Ther. 9, 643-653.

Kalliokoski, A. and Niemi, M. (2009) Impact of OATP transporters on pharmacokinetics. British journal of pharmacology 158, 693-705.

Lin, J. H. and Lu, A. Y. (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Br. J. Pharmacol. 35, 361-390.

Menochet, K., Kenworthy, K. E., Houston, J. B. and Galetin, A. (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab. Dispos. 40, 1744-1756.

Ofotokun, I. (2005) Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top. HIV Med. 13, 79-83.

Perez, G., Tabares, B., Jover, R., Gomez-Lechon, M. J. and Castell, J. V. (2003) Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol. In Vitro 17, 643-649.